Clinical and Immunological Features of the CMV Infection Atypical Course in Immunocompetent Individuals

Study Overview
=================
Brief Summary
-----------------
Current study evaluates possible correlations between the content of various cell populations, the genetic material of the virus and antibodies to it in the blood of patients and the risk of thrombosis development in patients with acute CMV infection. А new method for the early detection of immunological and clinical signs of thromboembolic complications of CMV infection in immunocompetent individuals and the treatment of patients in this category will be developed.

Detailed Description
-----------------
evaluate the immune status main indicators that characterize the activation of immune system, immunosuppression and anergy (myeloid suppressor cells, T-regulatory cells, T-cells according to the stages of differentiation (naive - effector - memory), activated T-cells); identify and characterize immunological disorders in patients with CMV infection complicated by thromboembolism of various localization; determine the presence and quantitative content in plasma / serum and neutrophils of the CMV genetic material by real-time PCR; study humoral immunity to CMV (IgM / IgG antibodies to CMV in serum); determine the content of CMV specific T-cells in peripheral blood; develop a method for the early detection of immunological and clinical signs of thromboembolic complications of CMV infection in immunocompetent persons and treatment of patients in this category.

Official Title
-----------------
To Identify the Clinical and Immunological Features of the CMV Infection Atypical Course in Immunocompetent Individuals and to Develop Methods for the Diagnosis and Treatment of Patients in This Category

Conditions
-----------------
CMV

Intervention / Treatment
-----------------
* Diagnostic Test: Bood leukocyte subsets
* Diagnostic Test: CMV specific T-cells
* Diagnostic Test: serum CMV IgM / IgG antibodies


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age 18 - 80 years; fever of not clear etiology confirmed CMV infection Exclusion Criteria: HIV infection taking hormones, cytostatics; drug addiction malignant neoplasms over the past 5 years. active viral hepatitis or liver cirrhosis; immunosuppressive conditions of any etiology

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with CMV infection<br> | Diagnostic Test: Bood leukocyte subsets<br>* Determination of blood leukocyte subpopulations: myeloid suppressor cells, T-regulatory cells, T-cells according to the stages of differentiation (naive - effector - memory), activated T-cells; circulating endothelial cells<br>Diagnostic Test: CMV specific T-cells<br>* CMV specific T-cells detected by flow cytometry<br>Diagnostic Test: serum CMV IgM / IgG antibodies<br>* serum CMV IgM / IgG antibodies detected by ELISA<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients with thrombosis | Thrombosis as a complication of CMV infection and its association with immune status, CMV specific T-cells count and CMV specific antibodies level | 1 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cytomegalovirus